Published in Cancer Gene Ther on January 03, 2014
Oncolytic viruses: From bench to bedside with a focus on safety. Hum Vaccin Immunother (2015) 1.01
Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc Natl Acad Sci U S A (2014) 0.87
Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis. Crit Rev Ther Drug Carrier Syst (2015) 0.86
Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy. Cancer Gene Ther (2014) 0.85
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. Viruses (2015) 0.84
Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. EBioMedicine (2016) 0.84
In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. Gene Ther (2015) 0.77
Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrob Agents Chemother (2016) 0.76
Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines. J Virol (2014) 0.76
Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic Virother (2017) 0.75
Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses. Hum Gene Ther (2014) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A (2001) 4.84
Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res (1996) 4.79
The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev (2001) 3.34
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol (2007) 2.80
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Oncolytic viruses. Nat Rev Cancer (2002) 2.10
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther (2005) 1.85
Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol (2000) 1.61
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 1.53
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 1.44
NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT. Cancer (1965) 1.43
Newcastle disease virus selectively kills human tumor cells. J Surg Res (1992) 1.40
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 1.18
Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol (2011) 1.12
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol (2009) 1.08
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer (2006) 1.08
Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol (2010) 1.07
Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg (2007) 1.05
Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther (2009) 1.04
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther (2007) 1.02
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01
An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res (2007) 1.00
A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother (1992) 0.98
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Res (2008) 0.91
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol (2008) 0.89
Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene (2010) 0.89
Velogenic newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol (2012) 0.89
Oncolytic viruses: an approved product on the horizon? Mol Ther (2010) 0.86
Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer (1994) 0.85
Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum Gene Ther (2012) 0.84
Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol (2012) 0.83
Type I interferons as radiosensitisers for pancreatic cancer. Eur J Cancer (2011) 0.82
Response of pancreatic cancer cells treated with interferon-alpha or beta and co-exposed to ionising radiation. Int J Radiat Biol (2010) 0.81
Characterization of trypsinogens 1 and 2 in two human pancreatic adenocarcinoma cell lines; CFPAC-1 and CAPAN-1. FEBS Lett (1991) 0.79
Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro. JOP (2012) 0.79
Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity. JOP (2012) 0.78
Synergistic antitumor effect of interferon-ß with gemcitabine in interferon-α-non-responsive pancreatic cancer cells. Int J Oncol (2011) 0.78
Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy. Cancer Gene Ther (2014) 0.85
A9 Deep sequencing analysis to investigate the importance of within host genetic diversity and evolution of influenza A viruses for the development of resistance against neuraminidase inhibitors. Virus Evol (2017) 0.75
A43 Modeling the ecology and evolution of H13 and H16 avian influenza A subtypes in black-headed gulls to understand influenza disease dynamics. Virus Evol (2017) 0.75